Mayne Pharma Group - Public Comps and Valuation Multiples

Mayne Pharma Group Overview

About Mayne Pharma Group

Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women’s Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women’s Health segment distributes branded women’s health products in the U.S. International’s segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.

Founded

2005

HQ

Employees

450

Website

maynepharma.com

Sectors

Small Molecules

Financials

LTM Revenue $267M

LTM EBITDA $30.0M

EV

$143M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Mayne Pharma Group Financials

As of November 2025, Mayne Pharma Group reported last 12-month revenue of $267M and EBITDA of $30.0M.

In the same period, Mayne Pharma Group achieved -$45.0M in LTM net income.

See Mayne Pharma Group valuation multiples based on analyst estimates

Mayne Pharma Group P&L

In the most recent fiscal year, Mayne Pharma Group reported revenue of $266M and EBITDA of $16.6M.

Mayne Pharma Group expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Mayne Pharma Group valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$267M	XXX	$266M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$161M	XXX	XXX	XXX
Gross Margin	n/a	XXX	60%	XXX	XXX	XXX
EBITDA	$30.0M	XXX	$16.6M	XXX	XXX	XXX
EBITDA Margin	11%	XXX	6%	XXX	XXX	XXX
EBIT	n/a	XXX	-$32.8M	XXX	XXX	XXX
EBIT Margin	n/a	XXX	-12%	XXX	XXX	XXX
Net Profit	-$45.0M	XXX	-$61.5M	XXX	XXX	XXX
Net Margin	-17%	XXX	-23%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Mayne Pharma Group including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $267M. EBITDA for the last twelve months was $30.0M. In the most recent fiscal year, Mayne Pharma Group achieved $266M in revenue and $16.6M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$267M	Analyst estimates available to subscribers	$266M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$161M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	60.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$30.0M	Analyst estimates available to subscribers	$16.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	11.3% EBITDA margin	Analyst estimates available to subscribers	6.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	n/a	Analyst estimates available to subscribers	-$32.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	n/a	Analyst estimates available to subscribers	-12.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$45.0M	Analyst estimates available to subscribers	-$61.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-16.9% net profit margin	Analyst estimates available to subscribers	-23.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Mayne Pharma Group

This financial data table provides comprehensive performance metrics for Mayne Pharma Group, a company based in Australia. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Mayne Pharma Group generated $267M in revenue over the last twelve months.
The company achieved $30.0M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$45.0M.

Fiscal Year Performance

In the most recent fiscal year, Mayne Pharma Group reported $266M in total revenue.
Fiscal year EBITDA was $16.6M.
The company maintained a gross profit margin of 60.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 6.2%.
Net profit margin reached -23.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Mayne Pharma Group. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Mayne Pharma Group Stock Performance

Mayne Pharma Group has current market cap of AUD 277M (or $181M), and EV of AUD 218M (or $143M).

Market Cap Evolution

Mayne Pharma Group Stock Data

As of December 3, 2025, Mayne Pharma Group's stock price is AUD 3 (or $2).

See Mayne Pharma Group trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$143M	$181M	XXX	XXX	XXX	XXX	$-0.75

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Mayne Pharma Group Valuation Multiples

Mayne Pharma Group's trades at 0.5x EV/Revenue multiple, and -7.1x EV/EBITDA.

See valuation multiples for Mayne Pharma Group and 15K+ public comps

Mayne Pharma Group Financial Valuation Multiples

As of December 3, 2025, Mayne Pharma Group has market cap of $181M and EV of $143M.

Equity research analysts estimate Mayne Pharma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Mayne Pharma Group has a P/E ratio of -4.0x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$181M	XXX	$181M	XXX	XXX	XXX
EV (current)	$143M	XXX	$143M	XXX	XXX	XXX
EV/Revenue	0.5x	XXX	0.5x	XXX	XXX	XXX
EV/EBITDA	4.8x	XXX	-7.1x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-2.3x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-4.0x	XXX	-2.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-9.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Mayne Pharma Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Mayne Pharma Group Margins & Growth Rates

Mayne Pharma Group's last 12 month revenue growth is 0%

Mayne Pharma Group's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.4M for the same period.

Mayne Pharma Group's rule of 40 is -8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Mayne Pharma Group's rule of X is 10% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Mayne Pharma Group and other 15K+ public comps

Mayne Pharma Group Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	0%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	11%	XXX	-8%	XXX	XXX	XXX
EBITDA Growth	-3%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-8%	XXX	-8%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	10%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.6M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	34%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	73%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial